ImmuneBiotech AB, the probiotic and microbiome company, is pleased to announce a fully subscribed investment in its recently completed financing.
“I’m very happy that we now have long-term and committed investors on board, with strong faith in our unique know-how and expertise in designing science-based probiotics. I’m particularly proud that more than 50% of our shareholders are female investors which is considered crucial for business success. This funding will give our company the stability to both expand our sales of GutMagnific® and to focus on our research to develop our Companion Probiotics® line” said Shahram Lavasani, CEO of ImmuneBiotech.
The funding will primarily be used to scale sales of its lead product GutMagnific®, a scientifically designed probiotic food supplement for Irritable Bowel Syndrome (IBS), one of the most common gut conditions affecting 15 % of the population. Besides IBS, GutMagnific® has potential in diarrhea, antibiotic induced diarrhea, Clostridium difficile infection (CDI) and Myalgic Encephalomyelitis (ME) also called Chronic Fatigue Syndrome (CFS) or post-viral fatigue. It has also the ability to target symptoms such as leaky gut and small intestine bacterial overgrowth (SIBO).
GutMagnific® is the first product in a new probiotic category ImmuneBiotics™ where products are developed using pharmaceutical precision focused on achieving a healthy balance between the microbiome, the immune system, and the intestinal barrier. Being first in this probiotic category, GutMagnific® has the potential to become a substantial player in the strongly growing probiotic supplement market, with global annual sales of USD 5 billion.
GutMagnific® is available to primarily Swedish and European consumers on the company’s own web-shop www.GutMagnific.com. The funds will be used to develop the digital marketing and also to reach major international markets for probiotic supplements through building various partnerships with retailers, distributors and licensees.
ImmuneBiotech will also allocate funding to finalize and disseminate data from the ongoing clinical study of GutMagnific® in ME/CFS. Furthermore, the funds will also be used to develop the pipeline of Companion Probiotics®, probiotic combinations designed to be used together with existing drugs for improved efficacy and reduced side-effects.